Guardant Health, Inc. (GH) News

Guardant Health, Inc. (GH): $53.81

1.40 (+2.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter GH News Items

GH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GH News Highlights

  • For GH, its 30 day story count is now at 16.
  • Over the past 27 days, the trend for GH's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
  • ALTO, DDOG and EPAM are the most mentioned tickers in articles about GH.

Latest GH News From Around the Web

Below are the latest news stories about GUARDANT HEALTH INC that investors may wish to consider to help them evaluate GH as an investment opportunity.

Will Guardant Health (GH) be Able to Sustain its Growth?

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund posted a return of -5.18% gross of fees compared to -3.60% return for the Russell 1000 Growth Index. Stock selection and security allocation led […]

Yahoo | November 28, 2022

Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Guardant Health (GH) and BridgeBio Pharma (BBIO)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intuitive Surgical (ISRG – Research Report), Guardant Health (GH – Research Report) and BridgeBio Pharma (BBIO – Research Report) with bullish sentiments. Intuitive Surgical (ISRG) J.P. Morgan analyst Robbie Marcus maintained a Buy rating on Intuitive Surgical yesterday and set a price target of $280.00. The company's shares closed last Thursday at $260.77. According to TipRanks.

Howard Kim on TipRanks | November 18, 2022

Guardant Health Third Quarter 2022 Earnings: EPS Misses Expectations

Guardant Health ( NASDAQ:GH ) Third Quarter 2022 Results Key Financial Results Revenue: US$117.4m (up 24% from 3Q...

Yahoo | November 9, 2022

How did Guardant Health Inc. (GH) fare last session?

While Guardant Health Inc. has underperformed by -0.15%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GH fell by -57.16%, with highs and lows ranging from $119.68 to $27.65, whereas the simple moving average fell by -12.07% in the last 200 days. On November 01, 2022, […]

US Post News | November 8, 2022

5 “Strong Buy” Stocks on Analysts’ Radars This Week

At a time when the future of companies is in a predicament, the million-dollar question is: which stocks do Wall Street analysts trust? We narrowed down five “Strong Buy” stocks using TipRanks’ Trending Stocks tool that tracks the most rated stocks during a specified period — Datadog (NASDAQ:DDOG), Guardant Health (NASDAQ:GH), Bill.com (NYSE:BILL), Epam Systems (NYSE:EPAM), and Papa John's (NASDAQ:PZZA). These stocks are on analysts’ radars this week. Datadog (DDOG) SaaS-based data monitoring and analytics platform Datadog has the backing of around 400 software platforms, including Amazon’s (NASDAQ:AMZN) Web Services and Microsoft's (NASDAQ:MSFT) Azure, all of which provide native support for Datadog's services.

Chandrima Sanyal on TipRanks | November 7, 2022

Guardant Health Inc. (NASDAQ:GH) Shares Plunged -5.83% In A Week – But Will They Keep Going Up?

In last trading session, Guardant Health Inc. (NASDAQ:GH) saw 1.93 million shares changing hands with its beta currently measuring 0.64. Company’s recent per share price level of $45.05 trading at -$0.73 or -1.59% at ring of the bell on the day assigns it a market valuation of $4.60B. That closing price of GH’s stock is … Guardant Health Inc. (NASDAQ:GH) Shares Plunged -5.83% In A Week – But Will They Keep Going Up? Read More »

Marketing Sentinel | November 4, 2022

Guardant Health Reports Third Quarter 2022 Financial Results

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2022. Recent Highlights Revenue of $117.4 million for the third quarter of 2022, an increase of 24% over the corresponding period of 2021 Reported 32,400 tests to clinical customers and 6,750 tests to

Business Wire | November 3, 2022

Guardant Health, Inc. (GH) Q3 2022 Earnings Call Transcript

Guardant Health, Inc. (NASDAQ:NASDAQ:GH) Q3 2022 Earnings Conference Call November 03, 2022 04:30 PM ET Company Participants Alex Kleban - Vice President, Investor Relations Helmy Eltoukhy…

Seeking Alpha | November 3, 2022

Guardant Health, Inc. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:GH)

The following slide deck was published by Guardant Health, Inc.

Seeking Alpha | November 3, 2022

Guardant Health reports Q3 mixed earnings; narrows FY22 guidance below estimates

Guardant Health press release (GH): Q3 Non-GAAP EPS of -$1.18 misses by $0.10.Revenue of $117.4M (+23.9% Y/Y) misses by $0.5M.Adjusted EBITDA loss was $112.8M for the third quarter…

Seeking Alpha | November 3, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4909 seconds.